1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Authors: ARODA VANITA R. , KRAUSE-STEINRAUF HEIDI , BUSE JOHN B. , GULANSKI BARBARA I. , FLOREZ HERMES , AHMANN ANDREW J. , LOVELAND AMY , KUHN ALEXANDER , LONIER JACQUELINE , MATHER KIEREN J. , WEXLER DEBORAH J. ,   GRADE RESEARCH GROUP
Published: June 2019

Background: GRADE enrolled 5,047 adults &gt; 30 years, T2DM &lt; 10 years duration, on metformin, requiring a second medication, A1C 6.8-8.5%. Age-related differences in disease phenotype may affect responses to the randomized treatments being evaluated.
Objective: To evaluate whether baseline characteristics differed by age.
Methods: Baseline characteristics were compared across age groups, using mean ± SD (ANOVA) or % (Pearson’s chi-square). We report nominal, unadjusted p-values.
Results: With the defined inclusion criteria, we enrolled a cohort with overall DM duration 4.2 ± 2.8 years, and A1c 7.5 ± 0.5%. Within this cohort, distinct clinical phenotypes by age were present. Across the age groups, older individuals had more CVD, and were on more medications for DM-related comorbidities. Younger individuals were more diverse, had higher weight, FPG, and insulin, more pronounced diabetic dyslipidemia, and were taking fewer medications for comorbidities (Table).
Conclusion: Within the GRADE cohort defined by inclusion criteria representing a specific stage of glycemia, the clinical phenotype of T2DM differed by age, with older participants having greater prevalent comorbidity and younger participants having more prominent hyperglycemia and higher weight. An understanding of the distinct phenotypes by age may identify priorities and gaps in clinical care.

Disclosure
V.R. Aroda: Consultant; Self; ADOCIA, AstraZeneca, Becton, Dickinson and Company, Novo Nordisk Inc., Sanofi, Zafgen, Inc. Employee; Spouse/Partner; Merck & Co., Inc. Research Support; Self; AstraZeneca, Calibra Medical, Eisai Inc., Janssen Research & Development, Novo Nordisk Inc., Sanofi, Theracos, Inc. H. Krause-Steinrauf: None. J.B. Buse: Consultant; Self; Neurimmune AG. Research Support; Self; AstraZeneca, National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk A/S, Sanofi, vTv Therapeutics. Stock/Shareholder; Self; Mellitus Health, PhaseBio Pharmaceuticals, Inc., Stability Health. Other Relationship; Self; ADOCIA, AstraZeneca, Dance Biopharm Holdings Inc., Eli Lilly and Company, MannKind Corporation, NovaTarg, Novo Nordisk A/S, Senseonics, vTv Therapeutics, Zafgen, Inc. B.I. Gulanski: None. H. Florez: None. A.J. Ahmann: Advisory Panel; Self; Eli Lilly and Company, MannKind Corporation, Novo Nordisk Inc., Sanofi-Aventis. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Medtronic. A. Loveland: None. A. Kuhn: None. J. Lonier: None. K.J. Mather: Advisory Panel; Self; Roche Diabetes Care. Research Support; Self; Abbott, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. D.J. Wexler: Other Relationship; Spouse/Partner; APOLO1BIO.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases